Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.
In a study in the journal Diabetes Technology & Therapeutics (DTT), investigators evaluated biomarkers for cardiovascular ...
According to a recent study, tirzepatide and semaglutide offer long-term health benefits but are not cost-effective.
Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...
A new study published in the New England Journal of Medicine suggests that tirzepatide, a medication originally developed for ...
More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®As previously a ...
University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity ...
MarketBeat on MSN4d
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback